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The extracellular accumulation of amyloid  (A) peptides is characteristic of Alzheimer’s disease (AD). However, formation of diffus-
ible, oligomeric formsofA, bothonandoff pathways to amyloid fibrils, is thought to includeneurotoxic species responsible for synaptic
loss andneurodegeneration, rather than polymeric amyloid aggregates. The 8-hydroxyquinolines (8-HQ) clioquinol (CQ) andPBT2were
developed for their ability to inhibit metal-mediated generation of reactive oxygen species fromA:Cu complexes and have both under-
gone preclinical and Phase II clinical development for the treatment of AD. Their respectivemodes of action are not fully understood and
may includeboth inhibitionofA fibrillarpolymerizationanddirectdepolymerizationof existingA fibrils. In thepresent study,we find
that CQ and PBT2 can interact directly with A and affect its propensity to aggregate. Using a combination of biophysical techniques, we
demonstrate that, in the presence of these 8-HQs and in the absence of metal ions, A associates with two 8-HQ molecules and forms a
dimer. Furthermore, 8-HQ bind Awith an affinity of 1–10M and suppress the formation of large (30 kDa) oligomers. The stabilized
lowmolecular weight species are nontoxic. Treatment with 8-HQs also reduces the levels of in vivo soluble oligomers in a Caenorhabditis
elegansmodel of A toxicity.Wepropose that 8-HQspossess an additionalmechanismof action that neutralizes neurotoxicA oligomer
formation through stabilization of small (dimeric) nontoxic A conformers.
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Introduction
Alzheimer’s disease (AD) is characterized by the accumulation of
the amyloid- (A) peptide within the extracellular space of the
brain (Masters et al., 1985; Kang et al., 1987). Although these
deposits of A are the pathognomonic feature of AD, the degree
of synaptic loss correlatesmorewith the soluble/diffusible species
of A oligomers (Lambert et al., 1998), which in turn are in
equilibrium with insoluble A aggregates (Mawuenyega et al.,
2010). This has led to the soluble oligomer theory of AD, where a
specific small, diffusible A oligomer causes synaptic damage
beyond the brain’s repair capacity. This theory has been sup-
ported by the finding of SDS-stable dimers in humanbrain tissue,
which affect LTP (Shankar et al., 2008), and the observation that
levels of a 56 kDa oligomer (labeled A 56*) correlate with the
severity of cognitive dysfunction (Lesne´ et al., 2006). There are
many different methods for generating toxic oligomers in vitro
(for review, see Benilova et al., 2012), which lead to a correspond-
ing array of numerous oligomeric forms of A, with little evi-
dence of which in vitro configurations actually exist in vivo, or are
specific to disease pathogenesis (for reviews, see Hayden and
Teplow, 2013; Ryan et al., 2013b). Despite this uncertainty, assays
of these oligomers and development of antibodies targeting the
A peptide have been a major theme in the recent efforts to
develop a therapy for AD (Imbimbo et al., 2012; Tayeb et al.,
2013).
Clioquinol (CQ; 5-chloro-7-iodo-quinolin-8-ol; Fig. 1A, in-
set), a first-generationmetal-protein attenuating compound and
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2-(dimethylamino)methyl-5,7-dichloro-8-hydroxyquinoline (PBT2;
Figure 1A, inset) (Telpoukhovskaia et al., 2014), a second-
generationmetal-protein attenuating compound that crosses the
blood–brain barrier (Padmanabhan et al., 1989; Adlard et al.,
2008), are examples of alternative approaches to targeting A in
the brain. This approach uses small molecules directed toward
inhibiting aberrant interactions of metals (e.g., Cu and Zn) and
A. PBT2has successfully completed twoPhase II clinical trials in
AD, the first of which has shownPBT2 to have significant positive
effects on cognitionwith concomitant reduction inCSFA levels
(Lannfelt et al., 2008; Faux et al., 2010). The results of the second
Phase II trial are currently being evaluated.
The initial proposed mechanisms of action for PBT2 and CQ
include a metal chaperone activity, inhibiting reactive oxygen
species generated from A:Cu complexes, inhibition of dity-
rosine cross-links, disaggregation of A amyloid fibrils, and pro-
moting uptake ofmetals by cells (Cherny et al., 2001;White et al.,
2006; Adlard et al., 2008; Bush, 2008; Crouch et al., 2011). Two
current studies have implicated the formation of ternary com-
plexes between 8-hydroxyquinoline (8-HQ), A, and a divalent
metal cation in the proposedmechanism of action (Kenche et al.,
2013; Matlack et al., 2014). It has also been observed that 8-HQs
affect the aggregation of a range of proteins, including the A
peptide (LeVine et al., 2009; Cheng et al., 2012),Huntingtin poly-
glutamine, TDP-43, and-synuclein (Tardiff et al., 2012)with no
addition of exogenousmetal ions. The direct, metal-independent
interaction of 8-HQs with Amay provide an additional mech-
anism of action (LeVine et al., 2009). Here we investigated the
effect of these compounds on oligomerization of A under
metal-free conditions. The in vivo effects of CQ and PBT2 were
also explored on a Caenorhabditis elegans model of A toxicity,
showing that hydroxyquinoline treatment results in a change in
the in vivo oligomeric status of A.
Materials andMethods
Human and mouse A1–42 was synthesized by theW. M. Keck Labora-
tory (Yale University, New Haven, CT) and its purity confirmed by high
performance liquid chromatography (HPLC) and mass spectrometry,
which indicated no significant oxidation or modification. N-terminally
fluorescein-tagged A was synthesized in-house using standard Fmoc
chemistry. Peptide identity and purity were confirmed by reverse-phase
HPLC and mass spectrometry. PBT2 was kindly donated by Prana Bio-
technology. CQ was purchased from Sigma (catalog #33931-100MG-R).
Solutions of both 8-HQs, PBS, Tris-HCl buffered saline, and water used
for buffer preparationwere confirmed to bemetal free (0.03M),with
inductively coupled plasma mass spectrometry (ICPMS). All other re-
agents were of analytical grade.
A1–42 preparation. A1–42 was resupended using a sodium hydro-
xide-based protocol as described previously (Ryan et al., 2013a). Briefly,
1 mg of peptide was resuspended in 200 l of 60 mM NaOH and incu-
bated for 5 min at room temperature. This solution was diluted with 700
l of distilled water and bath sonicated at room temperature for a further
5 min. The sonicated solution was neutralized with 100 l of 10 PBS,
pH 7 (50 mM sodium phosphate, 150 mM sodium chloride) and centri-
fuged at 14,000  g. The optical density at 214 nm of the supernatant,
containing the resolubilized A1–42, was determined with a quartz mi-
croplate and a Flexstation 3 plate reader (Molecular Devices) equipped
with absorbance optics. The concentration was calculated from the ab-
sorbance value at 214 nm using an extinction coefficient for A1–42 of
95,452 M1 cm1 (McColl et al., 2009). Peptide purity was determined
using matrix-assisted laser desorption/ionization-time of flight-mass
spectrometry (MALDI-TOFMS; Bruker). Recovery of A1–42 was typ-
ically 60%–80% based on dry weight of the peptide.
Thioflavin T (ThT) assays. The effect of PBT2 on the aggregation of
A1–42 was measured using a continuous ThT fluorescence assay de-
scribed previously (McColl et al., 2009; Ryan et al., 2012, 2013a).
PBT2/CQ was prepared as a 1 mM stock in DMSO, and diluted into PBS
containing ThT (10 M) to a final concentration of 10 M. A1–42 was
added to a final concentration of 5 M, and the plate was incubated at
37°C, with shaking every 7 min, for 3 s, before the measurement of the
ThT fluorescence intensity (444 nm excitation and 485 nm emission),
using a Flexstation 3 Plate reader. All measurements were conducted in
triplicate and averaged, and the experiment was repeated 4 times inde-
pendently, with different reagent batches. Controls where DMSO alone
was added were also conducted.
In addition, point-based-ThT measures were acquired to determine
50% inhibitory concentrations (IC50 values) and the effect of the 8-HQ
on preformed fibrils. To determine IC50 values, a series of solutions (in
triplicate) were prepared in 1.5 ml microcentrifuge tubes comprising 5
M A in PBS, pH 7.4, supplemented with 0, 0.8, 1.6, 3.25, 7.5, 10, or 15
Mof PBT2/CQ, and 10MThT. These solutions were incubated at 37°C
with shaking. After 24 h, 100l aliquots were transferred to 96well plates
and theThT fluorescence intensity (444 nmexcitation, 485 nmemission)
was measured in triplicate with the Flexstation 3 plate reader.
To investigate the effect of 8-HQs on preformed fibrils, A peptides (5
M) were incubated in 1 ml of PBS, 10 M ThT for 24 h at 37°C with
shaking. Increased ThT fluorescence, suggesting the presence of fibrils,
was confirmed using the above point-based assay. PBT2 and CQ were
added to a final concentration of 10 M, by adding 1 l of a 1 mM stock
solution per 100l of sample. Controls, where the equivalent amount of
DMSO was added, were also prepared. The solutions were incubated at
37°C with no shaking and periodically measured by the above point-
based assay.
Further analysis was conducted by centrifuging 100 l of A1–42
solutions incubated with the 8-HQs (after 24 h) or solutions where
hydroxyquinolines were added to preformed fibrils at 100,000 g for
30 min, and then quantifying the protein levels of the supernatant and
pellet with a BCA assay (Pierce). All measurements were performed in
triplicate.
Electronmicroscopy. Solutions from the continuous aggregation assays
were vortexed to suspend particulate matter, and an aliquot was spotted
onto carbon-coated copper grids (ProSciTech). The grids were washed
several times with distilled water to remove excess phosphate and then
allowed to air dry. The fibrils were negatively stained with 0.5% uranyl
acetate for 3 min and then washed several times with water. The samples
were analyzed on a Siemens ELMIS-KOP 102 electron microscope. The
films were scanned using a flatbed scanner and the resulting image saved
as a tiff file. These experiments were conducted in triplicate, from three
different experiments. Twenty images were taken across all grids to en-
sure that the selected images were representative of the sample.
Analytical ultracentrifugation experiments. Sedimentation experiments
were conducted at a concentration of 15 M A1–42 using an XL-I
analytical ultracentrifuge (Beckman Coulter). Sedimentation velocity
measurements were performed at 50,000 rpm and 20°C, using centrifuge
cells equipped with quartz windows and charcoal epon dual-sector cen-
terpieces and a sample volume of 300 l. The sedimentation velocity of
the 8-HQ compounds at various ratios with A1–42, solubilized and
prepared as described above using PBS as the buffering solution, was
investigated by acquiring a radial 350 nm absorbance scan every 7 min.
Sedimentation velocity analysis of A1–42 was measured specifically
by using fluorescein-labeled A, which was detected using a Fluores-
cence Detection System (Aviv Biomedicals), which constitutes a 488 nm
excitation laser and detection of fluorescence emission via a photomul-
tiplier tube equippedwith a 505 nm long-pass filter.With this system, the
fluorescence intensity of 15 M A1–42 peptide spiked with 1 nM
N-terminally fluorescein-labeled A1–42 in the presence and absence of
15M 8-HQwas acquired as a function of radial position every 2min for
the duration of the experiment. All velocity data were analyzed using a
continuous sedimentation coefficient distribution model [c(S)] and the
program SEDFIT version 9.4 (Schuck, 2000, 2003). The amount of sedi-
menting compound was assessed after baseline correction by taking the
average of the first 10 data points of the first scan of the run (total optical
density) and subtracting the average of the first 10 points of the final scan
(change in optical density). This was expressed as a proportion by divid-
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ing the by total optical density and was plotted as function of 8-HQ
concentration. The weight average sedimentation coefficient (Sw) was
assessed by integrating the c(S) distributions provided by SEDFIT, and
this value was also plotted as a function of PBT2 concentration.
Sedimentation equilibrium analysis was also performed. In contrast to
the sedimentation velocity, only 100 l of sample was loaded into the
centrifuge cells. Samples were spun at 26,000, 36,000, and 46,000 rpm,
and the concentration gradient formed over time at these speeds was
monitored using the absorbance at 230 nm. When the samples had
reached equilibrium (i.e., there was no change in the concentration gra-
dient over a period of 4 h), a high-quality scan was acquired, using a step
size of 10 m and averaging of 10 separate scans at 230 nm. With this
wavelength, there was a significant contribution of the compound absor-
bance. Data were analyzed using SedpHAT (Vistica et al., 2004) with a
model involving twomolecular weight (MW) populations, usingMWof
the hydroxyquinoline (305.5 for CQ, 271.2 for PBT2) as a fixed param-
eter. This experiment was repeated twice.
Size exclusion chromatography (SEC). SEC was conducted using an
Akta basic FPLC system and a 10 300mm Superdex S75 size exclusion
column (GE Healthcare). Samples containing 15 M A alone, 15 M
PBT2/CQalone, ormixtures of A and compoundwere loaded in 1ml of
PBS supplemented with 0.05 mM EDTA. The column was developed at a
flow rate of 1 ml per minute using 1 PBS, pH 7.4, 0.05 mM EDTA, and
the chromatogram was acquired using a flow absorbance detector set at
280 nm. The column was calibrated using the low MW calibration kit
fromGEHealthcare containing aprotinin (MW6.5 kDa), ribonuclease A
(MW13.7 kDa), carbonic anhydrase (MW29 kDA), ovalbumin (MW43
kDa), conalbumin (MW 75 kDa), and blue dextran (MW 2000 kDa).
Tomeasure the stability of the highMW species present in the absence
of hydroxyquinolines and the A-dimeric species induced by the pres-
ence of 8-HQs, corresponding fractions were collected and reapplied to
the SEC column after intervals of 1 and 2 h.
Small angle x-ray scattering (SAXS). SAXS measurements were ac-
quired at the SAXS/WAXS beamline of the Australian Synchrotron
(Kirby et al., 2013). Solutions of A1–42 (1 mg/ml, 221 M, in PBS) in
the presence and absence of 15 M 8-HQ were analyzed at a camera
length of 3.3 m corresponding to a range of momentum transfer 0.005
q 0.35 Å1 (where q 4sin/, 2 is the scattering angle, and  is the
x-ray wavelength: 1.03 Å at 12 KeV), using a Pilatus 1M detector (Dec-
tris). Data were normalized using an integrated beamstop and intensities
put on an absolute scale using distilled water as a standard. To limit
radiation damage, 10 frames of 1 s exposure were collected as 50 l
samples/buffers were flowed through a 1.5 mm quartz capillary. The
individual frames were compared for agreement before being averaged
with the scatterBrain IDL program (http://www.synchrotron.org.au/).
SAXS data were analyzed using the ATSAS software suite (Petoukhov
et al., 2007; Petoukhov et al., 2012), including the packages Primus
(Konarev et al., 2003) and GNOM, and ab initiomodels generated using
Dammif (Franke and Svergun, 2009). Ensemble optimization modeling
was conducted using ensemble optimization method (Bernado´ et al.,
2007) specifying a dimer of A1–42 for the ensemble generation.
Slot blot retention assay. A slot blot apparatus (Bio-Rad) was used as
per the manufacturer’s instructions. A nitrocellulose membrane (0.22
m) wetted with PBS was used as a filter. A1–42 at a concentration
of 5 M in 100 l of PBS was mixed with CQ ranging in concentration
from 0 to 25 M and applied to the slot blot apparatus. Each slot blot
well was washed thrice with PBS, and then the apparatus was disman-
tled and the membrane dried at room temperature. The retention
assay was performed in triplicate for each sample, and a total of three
replicate assays were conducted. The membranes were then imaged
using laser ablation (LA)-ICPMS (detailed methods below) or the
individual bands of retained material were excised and eluted off of
the membrane using 1% nitric acid. The resulting solution was ana-
lyzed by bulk ICPMS (detailed methods below). The ability of PBT2
to compete for the CQ binding site was assayed by supplementing the
A solution with PBT2 at a constant concentration of 10 M. The
affinity of PBT2 was then assayed by supplementing the A solution
with CQ at 10 M and titrating PBT2 from 0 to 50 M. All measure-
ments were conducted in triplicate.
LA-ICPMS. LA-ICPMS analysis and imaging were performed using a
NewWave Research UP213 laser ablation unit (Kennelec Scientific),
emitting a 213 nm laser pulse in the fifth harmonic. The ablated material
was directed to an Agilent 7500ce ICPMS (Mulgrave), fitted with “cs”
lenses for enhanced sensitivity. Imaging methods were adapted from
those previously described (Austin et al., 2009; Lear et al., 2012). Briefly,
a 100m laser beam diameter was rastered along the slot blotmembrane
at 300m/s. Iodine (m/z 127)wasmonitored in time-resolved analysis
mode. Images were produced using purpose-designed ISIDAS imaging
software (Hare et al., 2010, 2012).
Bulk ICPMS measurements. The elemental content of the retained
bands was also analyzed by bulk ICPMS measurements using an Agi-
lent 7700x ICPMS (Mulgrave). For typical instrument parameters,
refer to Hare et al. (2013) or Rembach et al. (2014). Briefly, the
membrane-containing retained material from the slot blot was care-
fully excised using surgical scissors and covered with 300 l of 1%
nitric acid. The samples were incubated at room temperature for 2 d,
and the solution containing the eluted material was carefully aspi-
rated into 1.5 ml Eppendorf tubes. These samples were introduced the
ICPMS using the integrated peristaltic pump sample introduction
system. Signals from iodine, copper, zinc, and iron were monitored
(m/z  126.9, 63.5, 65.4, and 55.8, respectively).
Binding analysis. The proportion of 8-HQ that is free and the propor-
tion that is bound to A can be determined from either the retention
data, as described above, or from the sedimentation velocity data, also as
described above. These data can be relatively easily analyzed by Equation
1, where the proportion of bound hydroxyquinoline per A (R) is given
by the maximal proportion of bound hydroxyquinoline (Bmax), the







This equation was fitted to the titration data using the nonlinear regres-
sion tools of Sigmaplot version 12.4, as described previously (Ryan et al.,
2011), and converted back to the change in the proportion of sediment-
ing PBT2 using mass action assumptions.
Analysis of weight average sedimentation coefficient. Analysis of the
change in weight average sedimentation coefficient was conducted in a
similar fashion to the methods of Schuck (2003). Briefly, the weight
average sedimentation coefficient (Sw) is proportion to the fractional
amount of each species that is present in the sedimenting population.
TheUV absorbance is arising from the hydroxyquinoline alone; thus, the
free A, which has no absorbance at 350 nm, is not affecting the weight
average sedimentation coefficient we observe. Assuming that the weight
average sedimentation coefficient at the highest concentration of PBT2 is
equivalent to that of the complex, we can use simple mass action laws to
determine the proportion of complex (AC) and free ligand (Cf). Thereby,
we can determine the amount of free A (Af) and the dissociation con-
stant (Kd). The two pertinent equations (Eqs. 2 and 3) are as follows:
Sw 	 fAC  SAC (2)
where fAC is the mol fraction of the A/PBT2 complex and SAC is the
sedimentation coefficient of the A/PBT2 complex (1.25 S). This equa-






to determine the dissociation constant for the complex, as described
previously (Schuck, 2003; Bailey et al., 2009; Mok et al., 2011).
NMR analysis. NMR spectra were acquired at 25°C on a Bruker-
BioSpin Avance 700 MHz spectrometer equipped with a cryogenically
cooled triple-resonance pulsed field gradient probe. Spectra were ob-
tained on samples that were typically 215 M A1–42 in 150 mM NaCl,
PBS at pH 7.0 in 1H2O:
2H2O (95:5). Spectra were referenced to 4,4-
dimethyl-4-silapentane-1-sulfonic acid at 0 ppm and processed with
TopSpin (Bruker-BioSpin).
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Multielectrode array (MEA) measurements of
A1–42 toxicity. For all MEA experiments, we
used an MEA2100 system (MultiChannel Sys-
tems), with ground plate heating set at 37°C
and 60MEA200/30iR-Ti chips (electrode grid:
8 8, 60 TiN electrodes; electrode spacing: 200
M; electrode diameter: 30 M; MultiChannel
Systems). Dissociated primary mouse cortical
neurons (E14) were plated (200,000 cells per
chip) and grown on poly-L-lysine-coated (1
mg/ml, prepared in borate buffer) MEA chips
using standard culture procedures for 2.5
weeks before experimentation. During this
time, the cultures were kept in a humidified
atmosphere (95% air, 5% CO2, 37°C), where
they formed stable neuronal networks. Cells
were removed from the incubator and baseline
levels of activity recorded for each individual
experiment (3 min; using MultiChannel Sys-
tems MC Rack version 4.5.13 software). Cells
were then replaced in the incubator for 	30
min before being removed and treated with ei-
ther A alone (3M final concentration on the
chip, n  6), or in combination with CQ (10
M final concentration on the chip, n  4).
Vehicle controls were performed separately
(n 2) and had no significant effect on activ-
ity. Cells were then returned to the incubator
for 24 h before a repeated measurement of lev-
els of activity (3 min). For each individual
experiment, the number of spikes and bursts
were recorded and values post-A and
post-A 
 CQ normalized to the baseline ac-
tivity for each experiment. Data were then an-
alyzed with GraphPad Prism 6 for Mac OS X
(version 6.0b).
Preparation of soluble fraction C. elegans ho-
mogenate. C. elegans strains GMC101, dvIs100
[pCL354(unc-54. DA-A1–42)
 pCL26(mtl-
2:GFP)], and CL2122; dvIs15(mtl-2:GFP) were
cultured on 8P media at 20°C as previously re-
ported (McColl et al., 2012). Embryos were
developmentally synchronized via alkaline hy-
pochlorite treatment of gravid adults and over-
night hatching of L1 larva in S-basal, 0.1 M
NaCl and 0.05 M KxPO3 buffer, pH 6.0
(Brenner, 1974). Approximately 50,000 L1 lar-
vae were transferred to 8P media for 24 h and
then an additional 24 h on 8PmediaPBT2 or
CQ, with DMSO as the vehicle (final concen-
tration 0.5% v/v). Populations were shifted to
25°C for 24 h to allow theA-induced paralysis
phenotype to manifest (McColl et al., 2012).
Samples were washed frommedia with S-basal,
and eggs, larvae, and debris were removed via
filtration through 40 mnylon filters (BD Sci-
ences). Approximately 0.5 ml (wet pellet) of
adults per replicate was frozen in liquid N2 for
lysis. Samples were disrupted in chilled PBS
(Invitrogen ), with an ice-chilled bath sonica-
tor (Bioruptor, Diagenode), using 5 on–off cy-
cles of 30 s durations on high power (320 W),
then clarified by ultracentrifugation (100,000  g for 30 min at 4°C).
Supernatant was removed and kept on ice or immediately used.
A oligomer ELISA assay. A oligomer levels were determined using
the sandwich ELISA with the same antibody used for both capture and
detection. The procedures and buffers are similar to those described
previously for the monomeric A ELISA (White et al., 2006; Lim et al.,
2011). The assay was conducted in 384 well, high-binding polystyrene
plates (Greiner). The plate was precoated with 25 l of 10 g/ml W02
monoclonal antibody (epitope A5–8) (Ida et al., 1996) in 50 mM so-
dium carbonate, pH 9.6, at 4°C overnight. After washingwith PBST (PBS
containing 0.05% Tween), the plate was blocked with 0.5% (w/v) casein
in PBS buffer, pH 7.4, tominimize nonspecific binding, andwashedwith
PBS before addition of samples andWO2-biotin (final concentration 0.3
g/ml, made from a 1mg/ml stock) and incubated overnight at 4°C. The
Figure 1. The effect of CQ and PBT2 on A1–42 aggregation. A, Aggregation of 5 M A1–42 was monitored by ThT
fluorescence in the absence (blue) and presence of 10M CQ (black) or PBT2 (red). Inset, I, Structure of PBT2. II, Structure of CQ.B,
Titration of the effective concentration for inhibition of ThT signal for CQ (black) and PBT2 (red) A1–42 alone is also plotted,
showing no significant change over the time frame (blue). C,D, E, Representative images of the grids for A1–42 alone (C) and in
thepresenceof CQ (D) andPBT2 (E). Images are representative	20 images acquiredover theEMgrids.F, Theeffect of 10MPBT2
(red) and CQ (black) on the ThT signal of preformed fibrils (blue represents 5M monomer equivalent, alone; t 0; open bars)
after 5 min of incubation (average of 3 measurements). G, The effect of 10 M PBT2 (red) and CQ (black) on the ThT signal of
preformed fibrils (blue represents 5Mmonomer equivalent, alone) over time (average of 3measurements).H, I, The proportion
of protein in the supernatant and pellet fractions of freshly refolded (H ) or fibrillar A (I ) incubated alone (blue) and in the
presence of CQ (black) or PBT2 (red) for 24 h.
2874 • J. Neurosci., February 18, 2015 • 35(7):2871–2884 Ryan et al. • Stabilization of Nontoxic A-Oligomers by 8-HQ
plate was washed with PBS and europium-labeled streptavidin (final
concentration 1 nM, made from a 10 M stock) added for 1 h at room
temperature. After a final wash, the plate was developed with a commer-
cial enhancement solution, which allows the europium to become fluo-
rescent. Time-resolved analysis was performed using a Wallac Victor 2
1420 Multilabel Plate Reader (PerkinElmer) with excitation at 340 nm
and emission at 613 nm, a delay of 400s, and ameasurementwindowof
400 s. Relative fluorescence levels minus the background were used for
each sample as an indication of the A oligomeric levels. Each measure-
ment was performed in triplicate.
Size exclusion analysis ofC. elegans homogenates.The supernatant ofC.
eleganshomogenate (100l) was applied to a 10 300mmSuperdex S75
size exclusion column (GE Healthcare) using an Agilent 1200 series
HPLC. The columnwas developed at a flow rate of 1ml perminute using
1 PBS, pH 7.4, 0.05 mM EDTA, and the chromatogram was acquired
using a flow absorbance detector set at 280 nm. Fractions (750 l) were
collected across the entire elution, and the
amount of monomeric A peptide in each
fraction was determined by sandwich ELISA,
following the protocol for the oligomer ELISA
described above, except that the detection an-
tibody was substituted for 1E8-biotin (epitope
17–22), which, as it has a different detection
epitope from the capture antibody (WO2), will
detect monomeric, oligomeric, and fibrillar
A1–42 peptides.
Results
The effect of PBT2 on
A self-association
Hydroxyquinoline effects on A1–42 fi-
bril formation were determined using a
continuous ThT assay. Measurements,
conducted in triplicate and averaged,
indicate that A1–42 alone followed a sig-
moidal increase in ThT fluorescence in-
tensity over a 20–24 h time period,
whereas A in the presence of CQ or
PBT2 did not produce a significant in-
crease in ThT fluorescence (Fig. 1A). This
was consistent with our previous studies
on inhibitory compounds (Ryan et al.,
2012). Inhibition was concentration de-
pendent, with an IC50 of	4.7 M and 5.1
M for CQ and PBT2, respectively (Fig.
1B). One possibility for this phenomenon
is that the hydroxyquinoline competes for
ThT-binding sites on A amyloid fibrils.
We tested this hypothesis by adding CQ
and PBT2 to preformed fibrils simultane-
ously with an equimolar amount of ThT
andmonitored the change in ThT fluores-
cence over time (Fig. 1C,D). Over short
time frames (5 min), there was no signifi-
cant change in ThT fluorescence; how-
ever, over longer time frames (24–48 h),
there was an	50% reduction in the fluo-
rescence intensity of the samples contain-
ing CQ or PBT2 compared with that of
A alone, which was not significantly
changed over the course of the experi-
ment. This was suggestive of longer time
processes, such as a disturbance of the
equilibria associated with fibril formation
toward nonfibrillar species, resulting in
a slow redistribution of A1–42 from
fibrillar to monomeric nonfibrillar species, rather than competi-
tion for binding sites, which would be expected to occur over
short time frames. Furthermore, electron micrographs of the
time course samples from Figure 1A (representative of three sep-
arate time course experiments, Fig. 1E–G) show the presence of
fibrillar aggregates only in the A1–42 alone samples; in the
A/CQ and A/PBT2 cases, there were no aggregates of any type
to be observed. These results are strongly indicative that these
8-HQ do not interfere with ThT binding directly, which is con-
sistent with previous results obtained with a radiolabeled form of
CQ that showed that ThT does not compete with 8-HQs for fibril
binding sites (Opazo et al., 2006). Further evidence for a loss of
amyloid, rather than competition with ThT, was provided by a
pelleting assay. The level of protein in the pellet fraction was
Figure 2. The effect of hydroxyquinolines on A1–42 self-association. A, The distribution of A1–42 species present in
samples of A1–42 alone (10M; blue line) or A1–42 (10M)mixedwith CQ (10M; black line) or PBT2 (10M; red line)was
analyzed by SEC using a 10 300 Superdex 75 column (flow rate 0.75ml/min, equilibrated in PBS). Inset, Full-scale plot. Arrows
indicate the migration of MW standards. Purple arrow indicates ribonuclease A (MW 13.7 kDa). Blue arrow indicates carbonic
anhydrase (MW 29 kDA). Red arrow indicates ovalbumin (MW 43 kDa). Orange arrow indicates conalbumin (MW 75 kDa). Gray
arrow indicates blue dextran (MW 2000 kDa). Black arrow indicates the migration of A1–42 monomer. B, Same as for A,
except that the samples are PBT2 (10 M; red line) and CQ (10 M; black line) alone. C, D, The stability of oligomers was
investigated by fractionating and reapplying the high MW oligomers formed by A1–42 alone (C) and the low MW oligomer
formedbyA1–42 in thepresenceof 8-HQ (D) after 1h (blue line) and2h incubation (red line). Theoriginal trace for both samples
fromA is provided for comparison (black line).E, Thedistribution of A1–42 species present in samples of A1–42alone (10M;
blue line) or A1–42 (10M)mixedwith equimolar CQ (black line) or equimolar PBT2 (red dashed line)was reinvestigated using
a sedimentation velocity experiment. F,G, Sedimentation equilibrium analysis of equimolar A1–42 in the presence of CQ (F ) or
PBT2 (G). Analysis of these data gives aMWof	10 kDa (calculated from fitting to a noninteracting speciesmodel in SedPhat12).
Solid lines indicate fit. Symbols represent every fourth data point.
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reduced 	50% upon treatment with hy-
droxyquinoline for 24 h, consistent with
the changes in the amount of ThT fluores-
cence (Fig. 1H), indicating a loss of aggre-
gated material as well as a loss of cross 
structure.
To further investigate the effect of
these 8-HQ on A1–42 self-association,
we used SEC under native conditions.
Freshly resuspended Awas confirmed to
exist as an equilibrium mixture of large
(30 kDa) and small (20 kDa) oligom-
ers (Fig. 2A; 60% high MW, 40% low
MW). Application of 1:1 A/8-HQ mix-
tures to the column resulted in the elution
of two major peaks with retention vol-
umes of 	18.8 and 21 ml, with no evi-
dence of the highMWspecies. The peak at
21 ml was replicated by conducting the
experiment in the presence of PBT2/CQ
only (Fig. 2B), indicating that this peak
represented the free ligand, whereas the
peak at 18.8 ml most likely represented a
small, lowMWA oligomer. Monomeric
A1–42 peptides eluted from this column
at	19.5 ml.
By fractionating the elution and reap-
plying the fractionated sample to the
column at various time intervals, we in-
vestigated the stability of the major oli-
gomers present in the samples. As the
major oligomer for A1–42 was centered
at	10 ml, a 2 ml fraction from 9 to 11 ml
wasmanually collected, and half was rein-
jected at 1 h, and after 2 h (Fig. 2C). Over
this time frame, the peak at 10 min slowly
disappeared, and the distribution shifted
to resemble the original SEC chromato-
gram of A1–42 alone. This indicated
that all of the oligomers in this sample
were in a slow equilibrium and that the
high MW species dissociated in the ab-
sence of low MW species. Similarly, the
8-HQ-stabilized species at 18 ml was col-
lectedmanually in a 2ml fraction from 17
to 19ml and reapplied to the SEC column
(Fig. 2D). Over this time frame, there was
a decrease in the peak at 18 ml, and the
appearance of both higher and lowerMW
peaks, consistent with dissociation of the
complex resulting in free CQ and A ca-
pable of self-associating into higher MW
peaks. This dissociation of the stabilized
species indicated that the dimer was not
stable in the absence of excess hydroxyquinolines, suggesting a
low-affinity interaction.
The effects of the 8-HQ on the aggregation state of A were
further explored using analytical ultracentrifugation (Fig. 2E–G).
Our previous work has shown that low MW A species are
formed upon addition of small amphipathic detergent molecules
to freshly prepared A, which is itself a heterogeneous mix of
small and large oligomers (Ryan et al., 2012). As PBT2 and CQ
absorb strongly in the UV range and could potentially bias the
analysis, we monitored the oligomeric status of A in solution
using trace amounts of fluorescently labeled A peptide. A
alone, as has previously been observed (Ryan et al., 2012), dis-
plays amain (	60%of the total) peak at 0.6 S (MW	5 kDa) and
a distribution of populations with sedimentation coefficients
ranging from5 to 50 S (Fig. 2E;MW	21–1000 kDa). Addition of
PBT2 or CQ suppressed the formation of large aggregates (sedi-
mentation coefficients 5–50 S) and shifted the low S peak from
0.6 S to 1.2 S (approximate MW of 10–15 kDa) (Fig. 2E). Sedi-
Figure 3. SAXS analysis of the A/CQ complex. A, SAXS data for A1–42 (0.2 mg/ml,	20M) in the presence of 20M CQ
was acquired at the Australian synchrotron.B, Guinier analysis of the CQ data inA. C, Kratky analysis of the CQ data inA.D,De novo
reconstruction of the scattering entity induced by CQ using Dammif. Line indicates overall dimension (Dmax). E, F, Ensemble
optimization modeling of the CQ-induced A1–42 dimers provides information on the distribution in the radius of gyration (Rg,
E) and maximal dimension (Dmax, F ) in relation to a pool of randomly generated structures: blue represents pool; red represents
selected structure parameters.G, SAXS data for A1–42 (0.2mg/ml,	20M) in the presence of 20M PBT2 (red squares)were
also acquired at the Australian synchrotron but had too high a ratio of signal-to-noise and thus were not of sufficient quality for
further analysis.
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mentation velocity measurements are affected by molecular
geometry so a sedimentation equilibrium experiment was con-
ducted to accurately determine the mass of the species. A in the
presence of PBT2 (Fig. 2F) or CQ (Fig. 2G) was determined to
have a molecular mass of 10.2  0.3 kDa and 9.95  0.26 kDa,
respectively. It is not possible to accurately assess the mass of A
alone using this method, as equilibrium between sedimentation
and diffusion is never reached, presumably because of an equi-
librium distribution between aggregated and nonaggregated
forms of A that changes over time.
The above results indicate that the presence of equimolar or
greater hydroxyquinolines induces the formation of a relatively
stable population of lowMW species of A. We chose to investi-
gate these species further using Synchrotron SAXS. A in the
presence of CQ provided high-quality data for analysis (Fig. 3A),
but A in the presence of PBT2 did not provide data of sufficient
quality (Fig. 3G) and, thus, was not used in this analysis. Guinier
analysis of the CQ:A SAXS data demonstrates that the complex
was clearly oligomeric, with an average radius of gyration (Rg) of
35.6 Å (Fig. 3B) [expected Rg for unfolded monomeric A1–42
based on sequence is 18.3Å (Kohn et al., 2004)], and aKratky plot
representation of the data is consistent with that expected for
partially unfolded A (Fig. 3C). The MW of the CQ:A complex
estimated from the forward scattering intensity (I0 0.010) was
	11–12 kDa, consistent with the results from analytical ultracen-
trifugation (AUC) and SEC. The particle distance distribution
function, P(r), was calculated via indirect Fourier transformation
of the scattering data with Gnom (Svergun, 1992) giving a max-
imumdiameter (Dmax) of 122.45Å and an average real spaceRg of
37.8 Å. De novo reconstruction of the shape of the CQ/A com-
plex was performed using the bead modeling program Dammif
(Franke et al., 2009), yielding extended structures with dimen-
sions consistent with dimeric A (Fig. 3D). The orientation of the
A1–42 molecules in the dimer cannot be determined by SAXS
analysis because of the nonsequence dependence of x-ray
scattering.
As the Kratky plot representation and the significantly ex-
tended ab initio model suggest a flexible system, an ensemble
approach tomodeling was subsequently conducted using the en-
semble optimization method (Bernado´ et al., 2007). This ap-
proach generates a pool of conformations (typically 10,000
structures) based on the input protein sequence, and specified
oligomerization state (in this case a dimer), and then uses a ge-
netic algorithm to select a subset of structures that best fit the
experimental SAXS data. This analysis provides distance distri-
butions (Rg and Dmax) that describe the predominant structural
features of the sample in solution. These distributions are shown
in Figure 3E, F, where the distributions for the selected structures
that fit the SAXS data (fit shown in Fig. 3A, red line) provide
relatively narrow distributions relative to the initial pool, with
modal values of 34.5 Å (Rg) and 128.6 Å (Dmax). These values are
larger than the modal value for the pool distribution indicating
that the CQ/A complex is not simply a distribution of random
coil dimeric structures, but a more specific extended dimeric
structure, and the narrow Rg/Dmax distributions also suggest that
the complex is at least partially folded.
Analysis of the interaction of 8-HQwith A
The ThT, pelleting, AUC, SEC, and SAXS results in combination
indicate that A in the presence of hydroxyquinoline is most
Figure 4. Investigation of the association of PBT2 and CQwith A1–42.A–C, Sedimentation velocity profiles acquired using 350 nm absorbance for PBT2 alone, PBT2
 0.5 equivalents of A,
and PBT2
 1.5 equivalents of A1–42, respectively. Data are normalized to provide better representation of the proportion of sedimentingmaterial.D, c(S) distributions for PBT2 in the absence
or in the presence of increasing proportions of A (15M PBT2, 15M A, black line; 7.5M PBT2, 15M A, red line; 5M PBT2, 15M A, orange line; 2.5M PBT2, 15M A, green line;
0.1MPBT2, 15MA, blue line). E, Proportion of sedimenting optical density as a function of CQ (dark green symbols) or PBT2 (dark red symbols) concentration. F,Weight average sedimentation
coefficient plotted as a function of CQ (dark green symbols) or PBT2 (dark red symbols) concentration. E, F, Lines through the data indicate fits of the equations described in the text and indicate a
Kd of	1–10M.
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likely a low MW complex, of approximately two 8-HQ (	700
Da) and two Amolecules (9024 Da), giving a stoichiometry of 1
hydroxyquinoline:Amolecule. These data, however, do not in-
dicate the affinity of A for 8-HQ. To address this, we initially
took advantage of inherent UV absorbance of the 8-HQ mole-
cules, which provide an excellent tool to monitor the association
of these compounds with A. Analyzing the absorbance unique
to a species in solution, such as PBT2 or CQ, is a powerful tool to
measure direct interactions, as exemplified by studies investigat-
ing the interaction of 7-nitrobenz-2-oxa-1,3-diazol-4-yl amino-
labeled phospholipids with apoC-II (Mok et al., 2011; Ryan et al.,
2011), or the interaction of Alexa-488 labeled DNA with Klenow
fragment (Bailey et al., 2009). PBT2 and CQ are particularly
suited to this approach because they have a low molecular mass
and do not sediment effectively in the aqueous-based buffer sys-
tems of the experiment. Figure 4 shows the absorbance of 15 M
PBT2 as a function of radial position in the absence of A (Fig.
4A), and PBT2 at 7.5M (Fig. 4B) and 22.5M in the presence of
15MA (Fig. 4C). The addition of A induces the formation of
boundaries in the absorbance data, which are dependent on the
concentration of PBT2. Similar data for CQ were also acquired
and showed a similar trend. This indicates that there is a specific
saturable interaction between these two molecules. From the ab-
sorbance of PBT2 (or CQ), we can estimate the amount of hy-
droxyquinoline required to saturate the sedimentation analysis
(	15 M), which gives a stoichiometry of 1:1 (Fig. 4D). Further
analysis of the data at the saturating concentration with the c(S)
model in SEDFIT9.4 showed that PBT2 and CQ were associated
with an A species having a sedimentation coefficient of 1.25
0.1 S (	11–14 kDa) (Fig. 4E). Thus, the observed complex has an
approximateMWof 10 kDa and consists of two A peptides and
two hydroxyquinoline molecules, giving a 2:2, or apparent 1:1,
Figure 5. Elemental analysis of the CQ interactionwith A1–42. A, LA-ICPMS detection of iodinewas used to generate an image of a slot blot assaywhere A1–42wasmixedwith increasing
concentrations of CQ (asmarked). Retained iodine is an integral part of CQ and is quantitative of the amount bound to A.B, The concentration dependence of iodine retention in the slot blot assay
obtained throughquantitationof the image inA, corrected for signal fromCQonly samples.C, Quantitationof retained iodine, obtained throughexcisionof bands on thenitrocellulose andextraction
using nitric acid and measurement using standard bulk ICPMS analysis. D, The retained CQ, determined by each method (red represents bulk ICPMS analysis; blue represents laser ablation ICPMS
analysis), was converted to proportion CQ bound per A, which was then plotted as a function of free CQ. This was analyzed to obtain a Kd of	1M. E, Retained CQ as a function of concentration
in the absence of A, LA-ICMPS. F, Retained CQ as a function of concentration in the absence of A, bulk ICMPS.G, Quantitation of retained iron, copper, and zinc, using the excision and extraction
ICPMSmethod.
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stoichiometry. Analysis of the concentration titration data for
both the proportion of sedimenting PBT2 and CQ, and the
weight average sedimentation coefficient (obtained by integrat-
ing the c(S) distributions, representative data for PBT2 shown in
Fig. 4D), indicated an apparent dissociation constant in the low
micromolar range (Fig. 4E and Fig. 4F, respectively), which is a
relatively weak interaction that appears to have a very significant
effect on the self-association of A.
There is a body of research using cell culture and electron
paramagetic resonance spectroscopy that suggests A is capable
of forming ametal ion-mediated ternary complexwith PBT2/CQ
(Kenche et al., 2013). The AUC and SEC results were performed
with buffers where the metal content is below the detection limit
of themethods used and in the presence of
an excess of EDTA. Under these condi-
tions, the formation of such a metal ion
ternary complex is unlikely; however, cat-
egorical, conclusive evidence for the ab-
sence of metal ion involvement in the
interaction is difficult to address using
these assays. Thus, we used ICPMS to de-
termine whether the A/hydroxyquino-
line was a ternary complex involving
metal ion or a metal independent binary
interaction. ICPMS analysis also provides
detection that is significantly more sensi-
tive and specific for the compound than
the other methods we have used. The ap-
proach involved a slot blot membrane re-
tention assay, similar to those used for
radioisotope measurements of protein-CQ
interactions (Opazo et al., 2006), where
the protein (A peptide) is mixed with an
increasing concentration of ligand (CQ)
and is applied to a nitrocellulose mem-
brane. Instead of using radiation counting
to detect the proportion of bound ligand,
we used ICPMS to measure the presence
of various elements, including iodine (as
the unique heteroatom component of
CQ), copper, zinc, and iron. For confir-
mation of our results, we did this analysis
via two different sample introduction
methods, in two separate locations. First,
we used LA-ICPMS to directly measure
the elements retained on the nitrocellu-
lose membrane, providing the image in
Figure 5A. Second, we used a digestion
protocol to solubilize the retained ele-
ments, and introduced this solubilized
material into the ICPMS with standard
liquid handling approaches (solution
nebulization ICPMS). The image in Fig-
ure 5A shows a clear trend where increas-
ing the concentration of CQ in theA/CQ
mixture results in increased retention of
iodine, consistent with the formation of a
CQ/A complex. This is quantified for
LA-ICPMS in Figure 5B, and for bulk
ICPMS in Figure 5C, corrected for reten-
tion of CQ alone by subtraction of the val-
ues shown in Figure 5E, F. Metal ions,
including iron, copper, and zinc, showed
no significant retention (Fig. 5D). As this is a retention assay and
we did not observe any metal present in our hydroxyquinoline,
A, or buffer reagents, this indicates that there is no metal re-
tained with the complex. Thus, these metal ions are not signifi-
cantly associated with the A/CQ complex and, under the
conditions used in this study, there is no evidence for the forma-
tion of a ternary complex between A, CQ, and a metal ion.
Retention of CQ in the absence of A was not significant at the
concentrations where CQ is soluble; however, at 50 M, where
CQ is insoluble, we observed appreciable iodine signal (shown in
Fig. 5E).
The retained iodine signal is directly proportional to the con-
centration of the A/CQ complex and consequently provides a
Figure 6. Elemental analysis of the PBT2 interaction with A1–42. A, Titration of PBT2 against a set concentration of CQ (10
M) in the presence of A1–42 (10M) resulted in a loss of iodine signal. Analysis of these data indicates a Kd of 1.1M for the
interaction of PBT2 and A. B, Quantitation of retained iron, copper, and zinc, measured using the bulk ICPMSmethod.
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measure of the free CQ. These data can be
plotted to produce a classical binding
curve (Fig. 5D). Nonlinear regression,
with a single site binding model, of these
data provides a stoichiometry of 1 CQ:1
A and a dissociation constant (Kd) of	1
M (R2  0.95 for LA-ICPMS, 0.91 for
solution nebulization ICPMS).
Relative affinity of PBT2 and CQ for A
As PBT2 does not contain iodine, we can-
not use the above retention assay to di-
rectly interrogate the affinity of PBT2 for
A. However, we can use competition be-
tween the CQ and PBT2 to determine the
relative affinity of these compounds for
A. Titration of PBT2 against a set con-
centration of 10MCQ in the presence of
A resulted in a concentration-dependent
decrease in the retained iodine signal,
consistent with a classic “cold” competi-
tion assay (Fig. 6A). Analysis of the data
with a standard one-site competitive binding
model provided an approximate equilibrium
inhibitor dissociation constant (Ki) of 1.1M
for the interaction of PBT2 to A. Consistent
with the CQ results, there was also no change
inthestatusofanyofthemetalionsupontitra-
tion of PBT2 (Fig. 6B).
Molecular analysis of the
A/PBT2 interaction
The observation of apparent hydroxy-
quinoline:A1–42 complexes with AUC,
SEC, and SAXS and an apparent dissocia-
tion constant of10M led us to attempt
nuclear magnetic resonance analysis of
the samples. Using natural isotopic abun-
dance in the peptide sample, concentra-
tions of 1–2 mg/ml (214–428 M) were
required for sufficient sensitivity, and this
precludes the use of CQ in these experi-
ments, as its solubility is 	30 M in our
buffers. PBT2 has no such constraint;
thus, these experiments were conducted
solely with this 8-HQ. The majority of the
A1–42 resonances are unperturbed in
the presence of the drug PBT2 (Fig. 7). In
the presence of one equivalent of PBT2 to A1–42, resonances
associated with PBT2 are significantly broadened with a small
chemical shift perturbation (0.04 ppm for themethyl resonances)
from the positions of PBT2 in the absence of A and reflect a very
low affinity interaction that is in intermediate exchange on the
NMR time scale under these conditions (Fig. 7).
Cellular toxicity of the hydroxyquinoline stabilized
A1–42 oligomer
To investigate the effect of these A/hydroxyquinoline com-
plexes on neuronal function and toxicity, we conducted anMEA
experiment (Fig. 8). This provides information on the effect of a
compound or peptide on a neuronal network. We specifically
investigated the spikes (Fig. 8A) and bursts (Fig. 8B) of activity in
culturedmouse primary cortical neurons after treatmentwithA
alone or Amixedwith approximately twofold concentrations of
CQ. A alone significantly decreased the activity of the neuronal
culture, consistent with previous measures of A toxicity to neu-
ronal cultures. Interestingly, addition of A and CQ not only
stopped the reduction in activity but also resulted in a significant
increase in activity, consistent with the stabilized A dimer being
nontoxic, and CQ enhancing the activity of neurons.
In vivo effects of PBT2 on A1–42 oligomerization in
C. elegans
In cell culture, we have shown that the stabilized complex is non-
toxic. To investigate the effect of 8-HQs in whole animal models
of A toxicity, we used a transgenicC. elegansmodel that displays
paralysis upon expression of A1–42. We previously reported
that PBT2 can reduce the toxicity of A1–42 in transgenic C.
Figure 7. 1D 1H NMR spectra of A1–42 in the presence and in the absence of PBT2. A, PBT2 alone. B, A1–42 with 1
equivalent PBT2. C, A1–42 alone. Spectra were acquired at 700 MHz in 150 mM PBS, pH 7.0, and 25°C.
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elegans (McColl et al., 2012). Consistent with the protective ef-
fects of 8-HQ, we determined that CQ was also able to signifi-
cantly reduce toxicity of human A1–42 expressed in the body
wall muscle cells (Fig. 9A). Using a range of concentrations, we
observed that 24 h exposure to 30 M PBT2/CQ provided a ro-
bust level of protection against A-induced paralysis. This treat-
ment significantly delays the onset of the toxic phenotype but
does not completely prevent it. This indicates that these com-
pounds can only partially rescue A toxicity in this model. Ini-
tially, we investigated the effect of 8-HQ compounds on A
oligomerization using an ELISA,which uses one antibody to both
capture and detect A (W02, epitope: A5–8) (Ida et al., 1996),
based on the assumption that only oligomeric forms of A will
display a second epitope for W0–2 to bind. The validity of this
assumption was determined by comparing the effects of equimo-
lar amounts of preaggregated A (which showed a high response
in the assay) against freshly prepared and denatured A, both of
which showed no response. Soluble lysates of C. elegans treated
with PBT2 or CQ had a significant (p 0.0001), but moderate,
20% reduction in the ELISA signal comparedwith untreated con-
trols (Fig. 9B). Although this was suggestive of an altered oli-
gomerization state upon treatment, this
assay is not quantitative, nor does it pro-
vide any indication of the molecular mass
of the oligomeric species. Thus, we also
examined soluble extracts of C. elegans
transgenics using size exclusion fraction-
ation on the Superdex 75 column (Fig.
9C). This analysis shows a clear and signif-
icant decrease in highMWA and a small
increase in low MW A species (quanti-
fied by measuring the area under each re-
spective peak; Fig. 9D), consistent with
the AUC and SEC observations described
above. Interestingly, the biologically de-
rived A oligomers appear larger than the
synthetically derived species. This may be
due to increased time to aggregate, a vari-
ety of post-translational modifications, or
any number of macromolecular interac-
tions that may occur in the complex bio-
logical milieu of a whole animal model.
Importantly, although treatment with
8-HQ altered the levels of soluble A oli-
gomers in vivo as predicted from the in
vitro studies, the treatment did not com-
pletely abolish the presence of A oligom-
ers in C. elegans. This result is consistent
with both partially reduced phenotype
rather than complete prevention of A-
induced toxicity (McColl et al., 2012) and
with the idea of 8-HQ having multiple
modes of action.
Discussion
We have investigated the 8-HQ (CQ) and
the novel 8-HQ compound PBT2 for
activity in modulating A1–42 self-
association and aggregation through a di-
rect interaction. Our aggregation assay
results show that these compounds are ca-
pable of inhibiting amyloid fibril forma-
tion (Fig. 1), and theAUC, SEC, and SAXS
results show that both PBT2 and CQ sup-
press large aggregates (Figs. 2 and 3) and appear to induce a low
MW species of A at 	1:1 stoichiometry (Figs. 2 and 3). The
formation of a stable 8-HQ/A complex, however, was not de-
tected by the NMR experiments (Fig. 7). These results parallel
other studies on hydroxyquinoline interactions with A, which
have shown that hydroxyquinoline-based compounds can in-
hibit aggregation (LeVine et al., 2009). In contrast to other stud-
ies on PBT2 andCQ interacting with A (Kenche et al., 2013), we
show that the interaction can be independent of divalent transi-
tion elements. Analysis of our buffers and reagents with ICPMS
indicates that divalent metal levels are insignificant (0.03 M)
and are not retained with the complex on nitrocellulose (Fig. 5).
Further support of this conclusion is provided by the size exclu-
sion results, in which the buffers contained 50 M EDTA and
where the same inhibition of aggregation and stabilization of low
MWspecies was observed as in experiments where EDTAwas not
present.
There are several toxicity studies, including LTP and mouse
cognition studies (Cherny et al., 2001; Adlard et al., 2008), cell
and yeast culture studies (Abramov et al., 2003; Tardiff et al.,
Figure 8. Assessment of the toxicity of CQ-induced A dimers by multielectrode array analysis. Recording of neuronal activity
in primarymouse neuronal cells treatedwith either A or A
 CQ. A, The total spike activity, normalized to baseline recordings
(set to 100%). B, The total number of bursts, normalized to baseline recordings (set to 100%). **p 0.01.
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2012; Matlack et al., 2014), and our previ-
ous C. elegans experiments (McColl et al.,
2012), indicating that A toxicity can be
attenuated in the presence of PBT2 or CQ.
We have reinvestigated the toxicity of
A1–42 in the presence of 8-HQ under
our experimental conditions (Fig. 8) and
have confirmed that the stabilized dimer
is nontoxic. Furthermore, our current
C. elegans results confirm a significant
change in the toxic phenotype observed
with A expression. The previous C. el-
egans experiments also indicated no sig-
nificant change in amyloid deposits
(McColl et al., 2012), although our cur-
rent results indicate a significant reduc-
tion in oligomeric species. These results
are consistent with the current A oli-
gomer hypothesis that oligomeric species
of A are toxic and while the amyloid
plaques/fibrils are not inherently toxic but
a consequence of the aberrant aggregation
of A (for review, seeHayden et al., 2013).
In particular, our results suggest that high
MW (i.e., 20–30 kDa, minimum stoi-
chiometry of a tetramer) oligomers repre-
sent the pool of toxic species, whereas low
MW oligomers (i.e., dimers) represent a
relatively nontoxic form of the peptide.
This is consistent with the observation
that tetramers may constitute the mini-
mum toxic species (Streltsov et al., 2011).
Furthermore, our data support the mech-
anism that 8-HQ can directly engage A oligomers and mono-
mers to ameliorate the activity of toxic high stoichiometry and
MW (30 kDa) soluble oligomers of A. The previous toxicity
(Abramov et al., 2003; Adlard et al., 2008; McColl et al., 2012;
Tardiff et al., 2012; Matlack et al., 2014) data in conjunction with
our toxicity data (Fig. 8) and characterization of A in the pres-
ence of 8-HQ, suggests that these stabilized low MW oligomers
are nontoxic. This further indicates that PBT2 and CQ not only
stabilize A and suppress aggregation but that these compounds
also neutralize large toxic A peptides and oligomers.
In addition to the currently exploredmechanisms of action of
PBT2 andCQ,we demonstrated that hydroxyquinolines have the
capability to directly influence the self-association and in vivo
toxicity of the A peptide. This activity is complimentary to the
other mechanisms of action described for PBT2, and particularly
correlates with the disaggregation of amyloid fibrils, inhibition of
reactive oxygen species generated by A copper complexes, and
inhibition of dityrosine crosslinks. The stabilization of nontoxic
A oligomers does not preclude a metal chaperone activity that
can occur in the complex biological milieu (Adlard et al., 2008;
Crouch et al., 2011) or an ionophoric activity resulting in promo-
tion of intracellular transition metal uptake by neurons. How-
ever, these results do indicate that 8-HQ have an additional
beneficial mode of action that relates to the formation and deg-
radation of toxic oligomeric species.
These results also raise some interesting questions in regards
to what the toxic oligomeric species may be. Our results suggest
that 8-HQ-stabilized low MW (dimeric) A oligomers are not
toxic, and the observations in the wider literature of a range of
oligomers (for review of A oligomerization, see Hayden et al.,
2013) having toxic properties suggest that synaptic loss in AD is
mediated by not a single oligomeric species, but a range of differ-
ent oligomers having varying degrees of toxicity, oligomeric sta-
tus, and solubility. This complexity may preclude identifying a
therapy targeted to a specific oligomer; as such, a targeted ap-
proach could miss a multitude of other toxic oligomeric species.
An alternative to targeting a specific oligomer for neutralization
or depletion is to stabilize a native, nontoxic, or nonpathogenic
form of the protein/peptide (for review, see Johnson et al., 2012).
This approach has been applied with great success to transthyre-
tin (TTR) systemic amyloidosis, where the natively folded TTR
tetramer slowly dissociates, generally under the influence of mu-
tation, to misfolded monomeric proteins that rapidly aggregate
via an energetically favorable “downhill” polymerization process
into amyloid fibrils (Colon and Kelly, 1992; Hurshman et al.,
2004; Foss et al., 2005; Johnson et al., 2005). In this pathway, the
rate-limiting step is the dissociation of the native tetramer (Foss
et al., 2005), and this has led to a significant effort to identify
methods to stabilize the native TTR conformation. This research
effort identified Tamafidis [2-(3,5-dichloro-phenyl)-benzoxa-
zole-6-carboxylic acid] for the treatment of TTR systemic amy-
loidosis in familial amyloid neuropathy (Johnson et al., 2012).
This compound acts by binding with high specificity and affinity
(	50 nM) to one of the thyroxine binding sites on TTR and
stabilizing the dimer–dimer interface of the tetramer through
hydrophobic and electrostatic interactions (Bulawa et al., 2012).
This prevents the dissociation of the tetramer and thus formation
of misfolded monomer and amyloid fibrils (Bulawa et al., 2012).
Tafamidis was shown to significantly slow progression of the dis-
ease process, including autonomic and peripheral neuropathies,
Figure9. 8-HQs affect A1–42 toxicity inmodel animals.A, The effect of CQon theparalysis phenotypeobserved in transgenic
C. elegans, where the number of animals trialed: n 105 (Ctl) and n 108 (CQ). ***p 0.001. B, ELISA quantitation of the
oligomeric status of A expressed in soluble lysates derived from C. elegans cultured in the absence or presence of 30M CQ or
PBT2. C, Size exclusion (Superdex S75, PBS, 0.75 ml/min) analysis of the oligomeric status of A1–42 in the soluble fraction of
lysates from transgenic C. elegans cultured in the absence (blue) or presence of 30M CQ (black) or PBT2 (red).D, Area under curve
analysis of thehighMW(elution volume	5–10ml) and lowMW(elution volume15–20ml) A1–42oligomers. Blue represents
transgenic C. elegans alone. Black represents CQ-treated transgenic C. elegans. Red represents PBT2-treated transgenic C. elegans.
*p 0.05, ***p 0.001.
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and improved autonomic nervous system function and cachexia
(Coelho et al., 2012, 2013). This efficacy proves the concept that
stabilization of a native, stable conformation can have significant
outcomes in proteinmisfolding diseases. AlthoughTTR follows a
different pathway from the typical nucleated polymerization
(NP) models applied to amyloidogenesis, the activation energy
for monomer dissociation is akin to the energy required to form
a nucleus in the NP model. This suggests that similar strategies,
where a nontoxic conformation is stabilized by the binding of
particular compounds, may be applicable to the wider range of
amyloid related diseases. In support of this theory, a recent study
on the effect of gallic acid interacting with -synuclein showed
that the binding of this compound prevented the collapse of the
protein into an aggregation prone form (Liu et al., 2014). Inter-
estingly, this interaction,while having large and significant effects
on the biophysics of the protein, also only displayed extremely
subtle effects when investigated by NMR (Liu et al., 2014). Our
results lend further support to these theories, suggesting that
PBT2/CQ variants have an additional mechanism of action
whereby A is stabilized in a nontoxic low MW form.
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